{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:00Z","timestamp":1789056360504,"version":"build-2803163510"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00648-4","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:07:07Z","timestamp":1789052827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From triggers to interfaces: polymer-stabilized nano-co-crystals for robust mesalazine delivery in UC."],"prefix":"10.1007","volume":"34","author":[{"given":"Arif","family":"khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil Rajnath","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kailasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"648_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01063-x","author":"V Solitano","year":"2025","unstructured":"Solitano V, Bernstein \u00c7N, Dotan I, Digna\u00df A, Domilici R, Dubinsky MC, et al. Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response. Nature Reviews Gastroenterology & Hepatology. 2025. https:\/\/doi.org\/10.1038\/s41575-025-01063-x.","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"648_CR2","doi-asserted-by":"publisher","unstructured":"Huntsman M, Lee SN, Stylli J, Stork C, Shimizu J, Quintana N, et al. Development of a Novel Drug Delivery System to Deliver Drugs Directly to the Colonic Mucosa, Resulting in Improved Efficacy and Reduced Systemic Exposure for the Treatment of UC. Crohn s & Colitis 360 2021;3. https:\/\/doi.org\/10.1093\/crocol\/otab045 .","DOI":"10.1093\/crocol\/otab045"},{"key":"648_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/jbcpp-2016-0014","volume":"29","author":"H Ahmad","year":"2018","unstructured":"Ahmad H, Kumar V. Pharmacotherapy of Ulcerative colitis - current status and emerging trends. Journal of Basic and Clinical Physiology and Pharmacology. 2018;29:581. https:\/\/doi.org\/10.1515\/jbcpp-2016-0014.","journal-title":"Journal of Basic and Clinical Physiology and Pharmacology"},{"key":"648_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/pharmaceutics17020226","volume":"17","author":"Y Gvozdeva","year":"2025","unstructured":"Gvozdeva Y, Staynova R. pH-Dependent Drug Delivery Systems for Ulcerative colitis Treatment. Pharmaceutics. 2025;17:226. https:\/\/doi.org\/10.3390\/pharmaceutics17020226.","journal-title":"Pharmaceutics"},{"key":"648_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4292\/wjgpt.v6.i4.137","volume":"6","author":"B Ye","year":"2015","unstructured":"Ye B. Mesalazine preparations for the treatment of Ulcerative colitis: Are all created equal? World Journal of Gastrointestinal Pharmacology and Therapeutics. 2015;6:137. https:\/\/doi.org\/10.4292\/wjgpt.v6.i4.137.","journal-title":"World Journal of Gastrointestinal Pharmacology and Therapeutics"},{"key":"648_CR6","doi-asserted-by":"publisher","unstructured":"Rajesh K, Deveswaran R, Srinivasan B, Basavaraj BV. Development of Mesalazine Microspheres for Colon Targeting. International Journal of Applied Pharmaceutics 2017;9:1. https:\/\/doi.org\/10.22159\/ijap.2017v9i4.17326 .","DOI":"10.22159\/ijap.2017v9i4.17326"},{"key":"648_CR7","doi-asserted-by":"publisher","unstructured":"Cam ME, G\u00fcler E, Abobakr FKM, Tasp\u0131nar YM, Bostan MS, Ero\u011flu MS. Evaluation of the mesalazine-loaded nanoparticles-embedded BSA hydrogels for the Ulcerative colitis treatment. Organic Communications 2024:133. https:\/\/doi.org\/10.25135\/acg.oc.171.2405.3240 .","DOI":"10.25135\/acg.oc.171.2405.3240"},{"key":"648_CR8","doi-asserted-by":"publisher","unstructured":"Dei\u00dfler H, Krammer H, Gillessen A. pH\u2011dependent vs. constant release of mesalazine in the treatment of Ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomedical Reports 2021;15. https:\/\/doi.org\/10.3892\/br.2021.1472 .","DOI":"10.3892\/br.2021.1472"},{"key":"648_CR9","doi-asserted-by":"publisher","unstructured":"Varum F, Freire AC, Fadda HM, Bravo R, Basit AW. A dual pH and microbiota-triggered coating (Phloral TM ) for fail-safe colonic drug release. International Journal of Pharmaceutics 2020;583:119379. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119379 .","DOI":"10.1016\/j.ijpharm.2020.119379"},{"key":"648_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","volume":"11","author":"S Hua","year":"2015","unstructured":"Hua S, Marks E, Schneider J, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue. Nanomedicine Nanotechnology Biology and Medicine. 2015;11:1117. https:\/\/doi.org\/10.1016\/j.nano.2015.02.018.","journal-title":"Nanomedicine Nanotechnology Biology and Medicine"},{"key":"648_CR11","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/pharmaceutics14122762","volume":"14","author":"A Gazzaniga","year":"2022","unstructured":"Gazzaniga A, Moutaharrik S, Filippin I, Foppoli A, Palugan L, Maroni A, et al. Time-Based Formulation Strategies for Colon Drug Delivery. Pharmaceutics. 2022;14:2762. https:\/\/doi.org\/10.3390\/pharmaceutics14122762.","journal-title":"Pharmaceutics"},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/nmo.12713","volume":"28","author":"A Haase","year":"2016","unstructured":"Haase A, Gregersen T, Christensen LA, Agnholt J, Dahlerup JF, Schlageter V, et al. Regional gastrointestinal transit times in severe Ulcerative colitis. Neurogastroenterology & Motility. 2016;28:217. https:\/\/doi.org\/10.1111\/nmo.12713.","journal-title":"Neurogastroenterology & Motility"},{"key":"648_CR13","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41598-021-81628-3","volume":"11","author":"O Zakerska-Banaszak","year":"2021","unstructured":"Zakerska-Banaszak O, Tomczak H, Gabryel M, Baturo A, Wolko \u0141, Michalak M, et al. Dysbiosis of gut microbiota in Polish patients with Ulcerative colitis: a pilot study. Scientific Reports. 2021;11:2166. https:\/\/doi.org\/10.1038\/s41598-021-81628-3.","journal-title":"Scientific Reports"},{"key":"648_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103606","volume":"28","author":"H Azehaf","year":"2023","unstructured":"Azehaf H, Benzine Y, Tagzirt M, Skiba M, Karrout Y. Microbiota-sensitive drug delivery systems based on natural polysaccharides for colon targeting. Drug Discovery Today. 2023;28: 103606. https:\/\/doi.org\/10.1016\/j.drudis.2023.103606.","journal-title":"Drug Discovery Today"},{"key":"648_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41564-021-01050-3","volume":"7","author":"RH Mills","year":"2022","unstructured":"Mills RH, Dulai PS, V\u00e1zquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, et al. Multi-omics analyses of the Ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nature Microbiology. 2022;7:262. https:\/\/doi.org\/10.1038\/s41564-021-01050-3.","journal-title":"Nature Microbiology"},{"key":"648_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12951-024-02724-w","volume":"22","author":"S Tang","year":"2024","unstructured":"Tang S, Wang W, Wang Y, Gao Y, Dai K, Zhang W, et al. Sustained release of 5-aminosalicylic acid from azoreductase-responsive polymeric prodrugs for prolonged colon-targeted colitis therapy. Journal of Nanobiotechnology. 2024;22:468. https:\/\/doi.org\/10.1186\/s12951-024-02724-w.","journal-title":"Journal of Nanobiotechnology"},{"key":"648_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1039\/d4sm01222d","volume":"21","author":"R Crispino","year":"2025","unstructured":"Crispino R, Lagreca E, Procopio A, D\u2019Auria R, Corrado B, Manna SL, et al. Advanced polymeric systems for colon drug delivery: from experimental models to market applications. Soft Matter. 2025;21:792. https:\/\/doi.org\/10.1039\/d4sm01222d.","journal-title":"Soft Matter"},{"key":"648_CR18","doi-asserted-by":"publisher","unstructured":"Current Update of Clinical Therapeutic Strategies for Colon-Targeted Delivery Systems. Pharmaceutical Sciences and Research 2024;11. https:\/\/doi.org\/10.7454\/psr.v11i1.1360 .","DOI":"10.7454\/psr.v11i1.1360"},{"key":"648_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17050547","volume":"17","author":"S Zhu","year":"2025","unstructured":"Zhu S, Yang Z, Liu Y, Cheng L, Long D, Dai F. Oral lipid nanoparticles for improving the efficiency of drug delivery systems in ulcerative colitis: recent advances and future prospects. Pharmaceutics. 2025;17:547. https:\/\/doi.org\/10.3390\/pharmaceutics17050547.","journal-title":"Pharmaceutics"},{"key":"648_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ces.2014.08.046","volume":"125","author":"JH Lee","year":"2014","unstructured":"Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chemical Engineering Science. 2014;125:75. https:\/\/doi.org\/10.1016\/j.ces.2014.08.046.","journal-title":"Chemical Engineering Science"},{"key":"648_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.addr.2018.10.005","volume":"138","author":"A Bordat","year":"2018","unstructured":"Bordat A, Boissenot T, Nicolas J, Tsapis N. Thermoresponsive polymer nanocarriers for biomedical applications. Advanced Drug Delivery Reviews. 2018;138:167. https:\/\/doi.org\/10.1016\/j.addr.2018.10.005.","journal-title":"Advanced Drug Delivery Reviews"},{"key":"648_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jsps.2014.10.001","volume":"24","author":"N Nidhi","year":"2014","unstructured":"Nidhi N, Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of Ulcerative colitis: A brief review. Saudi Pharmaceutical Journal. 2014;24:458. https:\/\/doi.org\/10.1016\/j.jsps.2014.10.001.","journal-title":"Saudi Pharmaceutical Journal"},{"key":"648_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.587012","volume":"7","author":"G Sanit\u00e1","year":"2020","unstructured":"Sanit\u00e1 G, Carrese B, Lamberti A. Nanoparticle surface functionalization: how to improve biocompatibility and cellular internalization. Front Mol Biosci. 2020;7:587012. https:\/\/doi.org\/10.3389\/fmolb.2020.587012.","journal-title":"Front Mol Biosci"},{"key":"648_CR24","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.3390\/molecules26113279","volume":"26","author":"I Nugrahani","year":"2021","unstructured":"Nugrahani I, Jessica MA. Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review. Molecules. 2021;26:3279. https:\/\/doi.org\/10.3390\/molecules26113279.","journal-title":"Molecules"},{"key":"648_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/bi.2018.33","volume":"8","author":"S Emami","year":"2018","unstructured":"Emami S, Siahi-Shadbad M, Adibkia K, Barzegar-Jalali M. Recent advances in improving oral drug bioavailability by cocrystals. Bioimpacts. 2018;8:305. https:\/\/doi.org\/10.15171\/bi.2018.33.","journal-title":"Bioimpacts"},{"key":"648_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejpb.2016.07.006","volume":"107","author":"M Karashima","year":"2016","unstructured":"Karashima M, Kimoto K, Yamamoto K, Kojima T, Ikeda Y. A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies. European Journal of Pharmaceutics and Biopharmaceutics. 2016;107:142. https:\/\/doi.org\/10.1016\/j.ejpb.2016.07.006.","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"648_CR27","doi-asserted-by":"publisher","first-page":"22286","DOI":"10.3390\/molecules201219851","volume":"20","author":"L Peltonen","year":"2015","unstructured":"Peltonen L, Strachan CJ. Understanding critical quality attributes for nanocrystals from preparation to delivery. Molecules. 2015;20:22286. https:\/\/doi.org\/10.3390\/molecules201219851.","journal-title":"Molecules"},{"key":"648_CR28","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1039\/d3ra00161j","volume":"13","author":"BA Witika","year":"2023","unstructured":"Witika BA, Choonara YE, Demana PH. A SWOT analysis of nano co-crystals in drug delivery: present outlook and future perspectives. RSC Advances. 2023;13:7339. https:\/\/doi.org\/10.1039\/d3ra00161j.","journal-title":"RSC Advances"},{"key":"648_CR29","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.apsb.2021.03.030","volume":"11","author":"M Guo","year":"2021","unstructured":"Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. Acta Pharmaceutica Sinica B. 2021;11:2537. https:\/\/doi.org\/10.1016\/j.apsb.2021.03.030.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"648_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1039\/d3tb02302h","volume":"12","author":"S Hu","year":"2023","unstructured":"Hu S, Zhao R, Xu Y, Gu Z, Zhu B, Hu J. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances. Journal of Materials Chemistry B. 2023;12:13. https:\/\/doi.org\/10.1039\/d3tb02302h.","journal-title":"Journal of Materials Chemistry B"},{"issue":"9","key":"648_CR31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70328","volume":"16","author":"DD Chavan","year":"2024","unstructured":"Chavan DD, Thorat VM, Shete AS, Patil SJ, Tiwari DD. Current perspectives on development and applications of cocrystals in the pharmaceutical and medical domain. Cureus. 2024;16(9): e70328. https:\/\/doi.org\/10.7759\/cureus.70328.","journal-title":"Cureus."},{"issue":"4","key":"648_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5599\/admet.1437","volume":"10","author":"K Muehlenweg","year":"2022","unstructured":"Muehlenweg K, Schaper E, Schwab M, Dressman J. Numerical modelling of the dissolution of drug nanocrystals and its application to industrial product development. ADMET DMPK. 2022;10(4):253\u201387. https:\/\/doi.org\/10.5599\/admet.1437.","journal-title":"ADMET DMPK."},{"issue":"7","key":"648_CR33","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/cg900129f","volume":"9","author":"N Schultheiss","year":"2009","unstructured":"Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(7):2950\u201367. https:\/\/doi.org\/10.1021\/cg900129f.","journal-title":"Cryst Growth Des."},{"issue":"5","key":"648_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s11894-010-0131-2","volume":"12","author":"YS Kim","year":"2010","unstructured":"Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010;12(5):319\u201330. https:\/\/doi.org\/10.1007\/s11894-010-0131-2.","journal-title":"Curr Gastroenterol Rep."},{"key":"648_CR35","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1038\/s41467-021-27463-6","volume":"12","author":"P Zhao","year":"2021","unstructured":"Zhao P, Xia X, Xu X, Leung KK, Rai A, Deng Y, et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Nature Communications. 2021;12:7162. https:\/\/doi.org\/10.1038\/s41467-021-27463-6.","journal-title":"Nature Communications"},{"key":"648_CR36","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.2174\/1381612824666180515125247","volume":"24","author":"H Yang","year":"2018","unstructured":"Yang H, Kim H, Jung S, Seo H-Y, Nida SK, Yoo S, et al. Pharmaceutical Strategies for Stabilizing Drug Nanocrystals. Current Pharmaceutical Design. 2018;24:2362. https:\/\/doi.org\/10.2174\/1381612824666180515125247.","journal-title":"Current Pharmaceutical Design"},{"key":"648_CR37","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s11095-023-03532-x","volume":"40","author":"K Shi","year":"2023","unstructured":"Shi K, Li M. Optimisation of Pharmaceutical Cocrystal Dissolution Performance through a Synergistic Precipitation Inhibition. Pharmaceutical Research. 2023;40:2051. https:\/\/doi.org\/10.1007\/s11095-023-03532-x.","journal-title":"Pharmaceutical Research"},{"key":"648_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/polym10030267","volume":"10","author":"TMM Ways","year":"2018","unstructured":"Ways TMM, Lau WM, Khutoryanskiy VV. Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers. 2018;10:267. https:\/\/doi.org\/10.3390\/polym10030267.","journal-title":"Polymers"},{"key":"648_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.biomaterials.2018.09.005","volume":"185","author":"AA Date","year":"2018","unstructured":"Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.09.005.","journal-title":"Biomaterials"},{"key":"648_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12272-020-01219-0","volume":"43","author":"M Naeem","year":"2020","unstructured":"Naeem M, Awan UA, Subhan F, Cao J, Hlaing SP, Lee J, et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Archives of Pharmacal Research. 2020;43:153. https:\/\/doi.org\/10.1007\/s12272-020-01219-0.","journal-title":"Archives of Pharmacal Research"},{"key":"648_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/biomedicines10010085","volume":"10","author":"P Liu","year":"2021","unstructured":"Liu P, Li Y, Wang R, Ren F, Wang X, Liu P, et al. Oxidative Stress and Antioxidant Nanotherapeutic Approaches for Inflammatory Bowel Disease. Biomedicines. 2021;10:85. https:\/\/doi.org\/10.3390\/biomedicines10010085.","journal-title":"Biomedicines"},{"key":"648_CR42","doi-asserted-by":"publisher","unstructured":"Du J, Zhang J, Wang L, Wang X, Zhao Y, Lu J, et al. Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during Ulcerative colitis. Nature Communications 2023;14. https:\/\/doi.org\/10.1038\/s41467-023-39173-2 .","DOI":"10.1038\/s41467-023-39173-2"},{"key":"648_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091935","volume":"10","author":"E Bankole","year":"2021","unstructured":"Bankole E, Read E, Curtis MA, Neves JF, Garnett JA. The relationship between mucins and ulcerative colitis: a systematic review. J Clin Med. 2021;10:1935. https:\/\/doi.org\/10.3390\/jcm10091935.","journal-title":"J Clin Med"},{"key":"648_CR44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s12276-023-00960-y","volume":"55","author":"C Song","year":"2023","unstructured":"Song C, Chai Z, Chen S, Zhang H, Zhang X, Zhou Y. Intestinal mucus components and secretion mechanisms: what we do and do not know. Experimental & Molecular Medicine. 2023;55:681. https:\/\/doi.org\/10.1038\/s12276-023-00960-y.","journal-title":"Experimental & Molecular Medicine"},{"key":"648_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12951-024-03066-3","volume":"23","author":"J Zhang","year":"2025","unstructured":"Zhang J, Yin Y-J, Wang X, Lu W, Chen Z, Yu C, et al. Adhesive polyelectrolyte coating through UV-triggered polymerization on PLGA particles for enhanced drug delivery to inflammatory intestinal mucosa. Journal of Nanobiotechnology. 2025;23:32. https:\/\/doi.org\/10.1186\/s12951-024-03066-3.","journal-title":"Journal of Nanobiotechnology"},{"key":"648_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12951-022-01539-x","volume":"20","author":"DA Subramanian","year":"2022","unstructured":"Subramanian DA, Langer R, Traverso G. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. Journal of Nanobiotechnology. 2022;20:362. https:\/\/doi.org\/10.1186\/s12951-022-01539-x.","journal-title":"Journal of Nanobiotechnology"},{"key":"648_CR47","doi-asserted-by":"publisher","unstructured":"Zhang J, Sun S, Chen H, Feng Y, Li Y, Dong Z. Advances in natural compound-based nanomedicine and the interaction with gut microbiota in Ulcerative colitis therapy. Frontiers in Pharmacology 2023;14. https:\/\/doi.org\/10.3389\/fphar.2023.1197144 .","DOI":"10.3389\/fphar.2023.1197144"},{"key":"648_CR48","doi-asserted-by":"publisher","unstructured":"Gangadi JR, Kokkula PK, Kannadasan M. Biodegradable polymers: A sustainable approach to colon drug delivery. International Journal of Pharmaceutical Chemistry and Analysis 2024;11:288. https:\/\/doi.org\/10.18231\/j.ijpca.2024.042 .","DOI":"10.18231\/j.ijpca.2024.042"},{"key":"648_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejpb.2021.07.014","volume":"167","author":"PM Veloso","year":"2021","unstructured":"Veloso PM, Machado R, Nobre C. Mesalazine and inflammatory bowel disease - From well-established therapies to progress beyond the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2021;167:89. https:\/\/doi.org\/10.1016\/j.ejpb.2021.07.014.","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"issue":"11","key":"648_CR50","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/j.2042-7158.2010.01030.x","volume":"62","author":"T Loftsson","year":"2010","unstructured":"Loftsson T, Brewster ME. Pharmaceutical solubilization of poorly water-soluble drugs. J Pharm Pharmacol. 2010;62(11):1560\u20137. https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01030.x.","journal-title":"J Pharm Pharmacol."},{"issue":"11","key":"648_CR51","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1440-1681.2007.04691.x","volume":"34","author":"R Canaparo","year":"2007","unstructured":"Canaparo R, Finnstrom N, Serpe L, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, small intestine and colon. Clin Exp Pharmacol Physiol. 2007;34(11):1156\u201365. https:\/\/doi.org\/10.1111\/j.1440-1681.2007.04691.x.","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"648_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114076","volume":"181","author":"A Awad","year":"2021","unstructured":"Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz ABM, et al. Clinical translation of advanced colonic drug delivery technologies. Advanced Drug Delivery Reviews. 2021;181: 114076. https:\/\/doi.org\/10.1016\/j.addr.2021.114076.","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"12","key":"648_CR53","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1365-2036.2004.02283.x","volume":"20","author":"A Raedler","year":"2004","unstructured":"Raedler A, Behrens C, Jewell DP. A 400 mg dose of oral mesalazine twice daily or 800 mg once daily in the maintenance treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;20(12):1353\u20138. https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02283.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"648_CR54","doi-asserted-by":"publisher","unstructured":"Vaezi Z, Ghavami SB, Farmani M, Mahdavian R, Aghdaei HA, Naderi-Manesh H. Oral formulation of 5-aminosalicylic acid-Hemoglobin bio-adhesive nanoparticles enhance therapeutic efficiency in Ulcerative colitis mice: A preclinical evaluation. Research Square (Research Square) 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3416624\/v1.","DOI":"10.21203\/rs.3.rs-3416624\/v1."},{"issue":"8","key":"648_CR55","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00042737-199808000-00003","volume":"10","author":"FN Hussain","year":"1998","unstructured":"Hussain FN, Ajjan RA, Morrow J, et al. Mesalazine: a review of its gastrointestinal pharmacokinetics. Eur J Gastroenterol Hepatol. 1998;10(8):635\u201343. https:\/\/doi.org\/10.1097\/00042737-199808000-00003.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"648_CR56","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/pharmaceutics14112385","volume":"14","author":"V Yadav","year":"2022","unstructured":"Yadav V, House A, Matiz S, McCoubrey LE, Bettano KA, Bhave L, et al. Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease. Pharmaceutics. 2022;14:2385. https:\/\/doi.org\/10.3390\/pharmaceutics14112385.","journal-title":"Pharmaceutics"},{"key":"648_CR57","doi-asserted-by":"publisher","unstructured":"Senjab RM, AlSawaftah N, Abuwatfa WH, Husseini GA. Advances in liposomal nanotechnology: from concept to clinics. RSC Pharmaceutics 2024;1:928. https:\/\/doi.org\/10.1039\/d4pm00176a .","DOI":"10.1039\/d4pm00176a"},{"key":"648_CR58","doi-asserted-by":"publisher","unstructured":"Akram W, Garud N. Design expert as a statistical tool for optimization of 5-ASA-loaded biopolymer-based nanoparticles using Box Behnken factorial design. Future Journal of Pharmaceutical Sciences 2021;7. https:\/\/doi.org\/10.1186\/s43094-021-00299-z .","DOI":"10.1186\/s43094-021-00299-z"},{"key":"648_CR59","doi-asserted-by":"publisher","unstructured":"Sreeharsha N, Narayan RH, Vijaya J, Nair AB. Proof-of-concept for Site-specific Delivery of Mesalamine Nanoparticles for Effective Therapy in Colitis. Indian Journal of Pharmaceutical Education and Research 2021;55. https:\/\/doi.org\/10.5530\/ijper.55.2s.116 .","DOI":"10.5530\/ijper.55.2s.116"},{"key":"648_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/mog.0000000000001064","volume":"41","author":"C Yeung","year":"2024","unstructured":"Yeung C, McCoubrey LE, Basit AW. Advances in colon-targeted drug technologies. Current Opinion in Gastroenterology. 2024;41:9. https:\/\/doi.org\/10.1097\/mog.0000000000001064.","journal-title":"Current Opinion in Gastroenterology"},{"key":"648_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejpb.2015.09.002","volume":"97","author":"CJ Andreas","year":"2015","unstructured":"Andreas CJ, Chen Y, Markopoulos C, Reppas C, Dressman J. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. European Journal of Pharmaceutics and Biopharmaceutics. 2015;97:39. https:\/\/doi.org\/10.1016\/j.ejpb.2015.09.002.","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"648_CR62","doi-asserted-by":"publisher","unstructured":"Goyanes \u00c1, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations. International Journal of Pharmaceutics 2015;484:103. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.02.051 .","DOI":"10.1016\/j.ijpharm.2015.02.051"},{"key":"648_CR63","doi-asserted-by":"publisher","unstructured":"Heikal EJ, Kaoud RM, Gad S, Mokhtar HI, Alattar A, Alshaman R, et al. Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery. Gels 2023;9:264. https:\/\/doi.org\/10.3390\/gels9040264 .","DOI":"10.3390\/gels9040264"},{"key":"648_CR64","doi-asserted-by":"publisher","unstructured":"Zhu C, Suarez SI, Lukesh JC. Illuminating and alleviating cellular oxidative stress with an ROS-activated, H2S-donating theranostic. Tetrahedron Letters 2021;69:152944. https:\/\/doi.org\/10.1016\/j.tetlet.2021.152944 .","DOI":"10.1016\/j.tetlet.2021.152944"},{"key":"648_CR65","doi-asserted-by":"publisher","unstructured":"Olaniyan MF, Muhibi MA, Olaniyan TB. Oxidative Stress and Inflammatory Response Interplay. Journal of Preventive Diagnostic and Treatment Strategies in Medicine 2023;2:94. https:\/\/doi.org\/10.4103\/jpdtsm.jpdtsm_73_23 .","DOI":"10.4103\/jpdtsm.jpdtsm_73_23"},{"key":"648_CR66","doi-asserted-by":"publisher","unstructured":"66. Franko N, Santinha AJ, Xue S, Zhao H, Hamri GC, Platt RJ, et al. Integrated compact regulators of protein activity enable control of signaling pathways and genome-editing in vivo. Cell Discovery 2024;10. https:\/\/doi.org\/10.1038\/s41421-023-00632-1 .","DOI":"10.1038\/s41421-023-00632-1"},{"key":"648_CR67","doi-asserted-by":"publisher","unstructured":"Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak S, et al. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate Ulcerative colitis. British Journal of Hospital Medicine 2021;82:1. https:\/\/doi.org\/10.12968\/hmed.2021.0399 .","DOI":"10.12968\/hmed.2021.0399"},{"key":"648_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00057-7","author":"MF Bayan","year":"2020","unstructured":"Bayan MF, Bayan RF. Recent advances in mesalamine colonic delivery systems. Future Journal of Pharmaceutical Sciences. 2020. https:\/\/doi.org\/10.1186\/s43094-020-00057-7.","journal-title":"Future Journal of Pharmaceutical Sciences"},{"key":"648_CR69","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s461977","author":"J Gao","year":"2024","unstructured":"Gao J, Li J, Luo Z, Wang H, Ma Z. Nanoparticle-based drug delivery systems for inflammatory bowel disease treatment. Drug Des Devel Ther. 2024. https:\/\/doi.org\/10.2147\/dddt.s461977.","journal-title":"Drug Des Devel Ther"},{"key":"648_CR70","doi-asserted-by":"publisher","unstructured":"Mehdi-Alamdarlou S, Mozafari N, Daneshamooz S, Ashrafi H. Preparation and in vitro evaluation of controlled release granules of mesalazine for colon targeted drug delivery system. DOAJ (DOAJ: Directory of Open Access Journals) 2022. https:\/\/doi.org\/10.30476\/tips.2021.92954.1116 .","DOI":"10.30476\/tips.2021.92954.1116"},{"key":"648_CR71","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1021\/ja02086a003","volume":"19","author":"AA Noyes","year":"1897","unstructured":"Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19:930\u20134. https:\/\/doi.org\/10.1021\/ja02086a003.","journal-title":"J Am Chem Soc"},{"key":"648_CR72","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s13346-023-01463-z","volume":"14","author":"L L\u00f3pez-Vidal","year":"2023","unstructured":"L\u00f3pez-Vidal L, Parodi P, Actis MR, Camacho N, Real DA, Paredes AJ, et al. Formulation and optimization of pH-sensitive nanocrystals for improved oral delivery. Drug Delivery and Translational Research. 2023;14:1301. https:\/\/doi.org\/10.1007\/s13346-023-01463-z.","journal-title":"Drug Delivery and Translational Research"},{"issue":"1","key":"648_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","volume":"47","author":"RH Muller","year":"2001","unstructured":"Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3\u201319. https:\/\/doi.org\/10.1016\/S0169-409X(00)00118-6.","journal-title":"Adv Drug Deliv Rev."},{"key":"648_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.03.003","volume":"117","author":"DJ Berry","year":"2017","unstructured":"Berry DJ, Steed JW. Pharmaceutical co-crystals, salts and multicomponent systems; intermolecular interactions and property based design. Adv Drug Deliv Rev. 2017;117:3\u201327. https:\/\/doi.org\/10.1016\/j.addr.2017.03.003.","journal-title":"Adv Drug Deliv Rev."},{"issue":"5","key":"648_CR75","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1021\/cg801039j","volume":"9","author":"DJ Good","year":"2009","unstructured":"Good DJ, Rodriguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 2009;9(5):2252\u201364. https:\/\/doi.org\/10.1021\/cg801039j.","journal-title":"Cryst Growth Des."},{"key":"648_CR76","doi-asserted-by":"publisher","first-page":"14126","DOI":"10.1039\/d5ra00216h","volume":"15","author":"S-N Kuo","year":"2025","unstructured":"Kuo S-N, Wu P, Huang S-L, Hsu Y, Huang J. Thermo-responsive methylcellulose\/hyaluronic acid-mesalamine hydrogel in targeted drug delivery for ulcerative colitis. RSC Adv. 2025;15:14126. https:\/\/doi.org\/10.1039\/d5ra00216h.","journal-title":"RSC Adv"},{"issue":"8","key":"648_CR77","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/jps.21650","volume":"98","author":"J Brouwers","year":"2009","unstructured":"Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549\u201372. https:\/\/doi.org\/10.1002\/jps.21650.","journal-title":"J Pharm Sci."},{"key":"648_CR78","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.dld.2024.04.012","volume":"56","author":"F D\u2019Amico","year":"2024","unstructured":"D\u2019Amico F, Lusetti F, Peyrin-Biroulet L, Danese S. MMX mesalamine in Ulcerative colitis: Major advantages towards classical mesalamine formulations. Digestive and Liver Disease. 2024;56:1425. https:\/\/doi.org\/10.1016\/j.dld.2024.04.012.","journal-title":"Digestive and Liver Disease"},{"issue":"11","key":"648_CR79","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1021\/acs.molpharmaceut.3c00334","volume":"20","author":"NP Mendis","year":"2023","unstructured":"Mendis NP, Lakerveld R. An in vitro model for cocrystal dissolution with simultaneous surface and bulk precipitation. Mol Pharm. 2023;20(11):5486\u201399. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00334.","journal-title":"Mol Pharm"},{"key":"648_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125298","volume":"671","author":"LM Newman","year":"2025","unstructured":"Newman LM, Kavanagh ON, Machado TC. DSPindex guides dose selection to extend drug supersaturation lifetime during cocrystal dissolution. Int J Pharm. 2025;671:125298. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125298.","journal-title":"Int J Pharm"},{"issue":"11","key":"648_CR81","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.3390\/pharmaceutics14112386","volume":"14","author":"A Budiman","year":"2022","unstructured":"Budiman A, Citraloka ZG, Muchtaridi M, et al. Inhibition of crystal nucleation and growth in aqueous drug solutions: impact of different polymers on supersaturation profiles of amorphous drugs. Pharmaceutics. 2022;14(11):2386. https:\/\/doi.org\/10.3390\/pharmaceutics14112386.","journal-title":"Pharmaceutics."},{"issue":"7","key":"648_CR82","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1021\/bm800276d","volume":"9","author":"IA Sogias","year":"2008","unstructured":"Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules. 2008;9(7):1837\u201342. https:\/\/doi.org\/10.1021\/bm800276d.","journal-title":"Biomacromolecules"},{"issue":"1\u20133","key":"648_CR83","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0378-5173(92)90353-4","volume":"78","author":"CM Lehr","year":"1992","unstructured":"Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and other natural polymers. Int J Pharm. 1992;78(1\u20133):43\u20138. https:\/\/doi.org\/10.1016\/0378-5173(92)90353-4.","journal-title":"Int J Pharm."},{"issue":"22","key":"648_CR84","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1007\/s00018-011-0822-3","volume":"68","author":"MEV Johansson","year":"2011","unstructured":"Johansson MEV, Ambort D, Pelaseyed T, et al. Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci. 2011;68(22):3635\u201341. https:\/\/doi.org\/10.1007\/s00018-011-0822-3.","journal-title":"Cell Mol Life Sci."},{"issue":"6","key":"648_CR85","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","volume":"64","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557\u201370. https:\/\/doi.org\/10.1016\/j.addr.2011.12.009.","journal-title":"Adv Drug Deliv Rev."},{"key":"648_CR86","doi-asserted-by":"publisher","unstructured":"Murgia X, Loretz B, Hartwig O, Hittinger M, Lehr CM. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv Drug Deliv Rev. 2018;124:82\u201397. https:\/\/doi.org\/10.1016\/j.addr.2017.10.009","DOI":"10.1016\/j.addr.2017.10.009"},{"issue":"30","key":"648_CR87","doi-asserted-by":"publisher","first-page":"18864","DOI":"10.1074\/jbc.273.30.18864","volume":"273","author":"MAB Axelsson","year":"1998","unstructured":"Axelsson MAB, Asker N, Hansson GC. O-glycosylated MUC2 monomer and dimer from LS 174T cells are water-soluble, whereas larger MUC2 species are insoluble. J Biol Chem. 1998;273(30):18864\u201370. https:\/\/doi.org\/10.1074\/jbc.273.30.18864.","journal-title":"J Biol Chem."},{"key":"648_CR88","doi-asserted-by":"publisher","unstructured":"Pawar VK, Panchal SB, Singh Y, et al. Immunotherapy of cancer with ligand functionalized polymeric nanoparticles. J Control Release. 2013;170(1):77\u201394. https:\/\/doi.org\/10.1016\/j.jconrel.2013.04.017","DOI":"10.1016\/j.jconrel.2013.04.017"},{"key":"648_CR89","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cgh.2006.10.025","volume":"5","author":"GR Lichtenstein","year":"2007","unstructured":"Lichtenstein GR, Kamm MA, Boddu P, Gubergrits NB, Lyne A, Butler T, et al. Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative colitis. Clinical Gastroenterology and Hepatology. 2007;5:95. https:\/\/doi.org\/10.1016\/j.cgh.2006.10.025.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"648_CR90","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","volume":"26","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System\u00ae mesalazine for the induction of remission in patients with mild-to\u2010moderate ulcerative colitis: a combined analysis of two randomized, double\u2010blind, placebo\u2010controlled trials. Aliment Pharmacol Ther. 2007;26:205. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03361.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"648_CR91","doi-asserted-by":"publisher","unstructured":"Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in Ulcerative colitis. Gut 2008;57:893. https:\/\/doi.org\/10.1136\/gut.2007.138248 .","DOI":"10.1136\/gut.2007.138248"},{"key":"648_CR92","doi-asserted-by":"publisher","unstructured":"Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of Ulcerative colitis. Expert Review of Clinical Pharmacology 2012;5:113. https:\/\/doi.org\/10.1586\/ecp.12.2 .","DOI":"10.1586\/ecp.12.2"},{"key":"648_CR93","doi-asserted-by":"publisher","unstructured":"Hussain N. Regulatory aspects in the pharmaceutical development of nanoparticle drug delivery systems designed to cross the intestinal epithelium and M-cells. International Journal of Pharmaceutics 2016;514:15. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.07.053 .","DOI":"10.1016\/j.ijpharm.2016.07.053"},{"key":"648_CR94","doi-asserted-by":"publisher","unstructured":"Sahoo RN, De A, Kataria V, Mallick S. Solvent-free Hot Melt Extrusion Technique in Improving Mesalamine Release for Better Management of Inflammatory Bowel Disease. Indian Journal of Pharmaceutical Education and Research 2019;53. https:\/\/doi.org\/10.5530\/ijper.53.4s.150 .","DOI":"10.5530\/ijper.53.4s.150"},{"key":"648_CR95","doi-asserted-by":"publisher","unstructured":"Alshammari ND, Elkanayati RM, Vemula SK, Shawakri EA, Uttreja P, Almutairi M, et al. Advancements in Colon-Targeted Drug Delivery: A Comprehensive Review on Recent Techniques with Emphasis on Hot-Melt Extrusion and 3D Printing Technologies. AAPS PharmSciTech 2024;25:236. https:\/\/doi.org\/10.1208\/s12249-024-02965-w .","DOI":"10.1208\/s12249-024-02965-w"},{"key":"648_CR96","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02749-2","author":"H Patil","year":"2024","unstructured":"Patil H, Vemula SK, Narala S, Lakkala P, Munnangi SR, Narala N, et al. Hot-melt extrusion: from theory to application in pharmaceutical formulation-where are we now? AAPS PharmSciTech. 2024. https:\/\/doi.org\/10.1208\/s12249-024-02749-2.","journal-title":"AAPS PharmSciTech"},{"key":"648_CR97","doi-asserted-by":"publisher","unstructured":"Bayan MF, Marji SM, Salem MS, Begum MY, Chidambaram K, Chandrasekaran B. Development of Polymeric-Based Formulation as Potential Smart Colonic Drug Delivery System. Polymers 2022;14:3697. https:\/\/doi.org\/10.3390\/polym14173697 .","DOI":"10.3390\/polym14173697"},{"key":"648_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118723","volume":"572","author":"A Foppoli","year":"2019","unstructured":"Foppoli A, Maroni A, Moutaharrik S, Melocchi A, Zema L, Palugan L, et al. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. International Journal of Pharmaceutics. 2019;572: 118723. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118723.","journal-title":"International Journal of Pharmaceutics"},{"key":"648_CR99","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1208\/s12249-020-01713-0","volume":"21","author":"J Mati\u0107","year":"2020","unstructured":"Mati\u0107 J, Paudel A, Bauer H, Garc\u00eda RAL, Biedrzycka K, Khinast J. Developing HME-Based Drug Products Using Emerging Science: a Fast-Track Roadmap from Concept to Clinical Batch. AAPS PharmSciTech. 2020;21:176. https:\/\/doi.org\/10.1208\/s12249-020-01713-0.","journal-title":"AAPS PharmSciTech"},{"key":"648_CR100","doi-asserted-by":"publisher","unstructured":"Rajadhyax AB, Shinde U, Desai HR, Mane S. Hot Melt Extrusion in Engineering of Drug Cocrystals: A Review. Asian Journal of Pharmaceutical and Clinical Research 2021:10. https:\/\/doi.org\/10.22159\/ajpcr.2021.v14i8.41857 .","DOI":"10.22159\/ajpcr.2021.v14i8.41857"},{"key":"648_CR101","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","volume":"353","author":"LE McCoubrey","year":"2022","unstructured":"McCoubrey LE, Favaron A, Awad A, Orlu M, Gaisford S, Basit AW. Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics. Journal of Controlled Release. 2022;353:1107. https:\/\/doi.org\/10.1016\/j.jconrel.2022.12.029.","journal-title":"Journal of Controlled Release"},{"key":"648_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/18722113113079990014","volume":"8","author":"I Kadiyala","year":"2014","unstructured":"Kadiyala I, Jacobs DH. The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease. Recent Patents on Drug Delivery & Formulation. 2014;8:3. https:\/\/doi.org\/10.2174\/18722113113079990014.","journal-title":"Recent Patents on Drug Delivery & Formulation"},{"key":"648_CR103","doi-asserted-by":"publisher","DOI":"10.1097\/mib.0b013e3182920108","volume":"19","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews. Inflamm Bowel Dis. 2013;19:1. https:\/\/doi.org\/10.1097\/mib.0b013e3182920108.","journal-title":"Inflamm Bowel Dis"},{"key":"648_CR104","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jconrel.2024.04.016","volume":"369","author":"LE McCoubrey","year":"2024","unstructured":"McCoubrey LE, Seegobin N, Sangfuang N, Moens F, Duyvejonck H, Declerck E, et al. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome. Journal of Controlled Release. 2024;369:630. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.016.","journal-title":"Journal of Controlled Release"},{"key":"648_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2021.130464","volume":"424","author":"Z Li","year":"2021","unstructured":"Li Z, Wang F, Cai Z, Zhou Q, Chen B, Zhang C, et al. Improving drug utilization platform with injectable mucoadhesive hydrogel for treating Ulcerative colitis. Chemical Engineering Journal. 2021;424: 130464. https:\/\/doi.org\/10.1016\/j.cej.2021.130464.","journal-title":"Chemical Engineering Journal"},{"key":"648_CR106","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3390\/pharmaceutics13050759","volume":"13","author":"A Melocchi","year":"2021","unstructured":"Melocchi A, Uboldi M, Vangosa FB, Moutaharrik S, Cerea M, Foppoli A, et al. The Chronotopic TM System for Pulsatile and Colonic Delivery of Active Molecules in the Era of Precision Medicine: Feasibility by 3D Printing via Fused Deposition Modeling (FDM). Pharmaceutics. 2021;13:759. https:\/\/doi.org\/10.3390\/pharmaceutics13050759.","journal-title":"Pharmaceutics"},{"key":"648_CR107","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/s2468-1253(18)30231-0","volume":"3","author":"N Nguyen","year":"2018","unstructured":"Nguyen N, Fum\u00e9ry M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate Ulcerative colitis: a systematic review and network meta-analyses. The Lancet Gastroenterology & Hepatology. 2018;3:742. https:\/\/doi.org\/10.1016\/s2468-1253(18)30231-0.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"648_CR108","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/jgh3.12935","volume":"7","author":"K Paridaens","year":"2023","unstructured":"Paridaens K, Fullarton J, Travis S. Efficacy of oral prolonged-release mesalazine in moderately active UC. JGH Open. 2023;7:516. https:\/\/doi.org\/10.1002\/jgh3.12935.","journal-title":"JGH Open"},{"key":"648_CR109","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3680606","author":"B Barberio","year":"2020","unstructured":"Barberio B, Segal J, Quraishi MN, Black CJ, Savarino E, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative colitis: Systematic Review and Network Meta-Analysis. SSRN Electronic Journal. 2020. https:\/\/doi.org\/10.2139\/ssrn.3680606.","journal-title":"SSRN Electronic Journal"},{"key":"648_CR110","doi-asserted-by":"publisher","unstructured":"Hua S. Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors. Frontiers in Pharmacology 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.00524 .","DOI":"10.3389\/fphar.2020.00524"},{"key":"648_CR111","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijpharm.2018.06.054","volume":"548","author":"GB Hatton","year":"2018","unstructured":"Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. International Journal of Pharmaceutics. 2018;548:408. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.054.","journal-title":"International Journal of Pharmaceutics"},{"key":"648_CR112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2018.05.007","volume":"281","author":"A Teruel","year":"2018","unstructured":"Teruel A, P\u00e9rez-Esteve \u00c9, Gonz\u00e1lez\u2010\u00c1lvarez I, Gonz\u00e1lez\u2010\u00c1lvarez M, Costero AM, Ferri D, et al. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: new approaches for inflammatory bowel diseases treatment. J Control Release. 2018;281:58. https:\/\/doi.org\/10.1016\/j.jconrel.2018.05.007.","journal-title":"J Control Release"},{"key":"648_CR113","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","volume":"16","author":"S Amidon","year":"2015","unstructured":"Amidon S, Brown J, Dave VS. Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches. AAPS PharmSciTech. 2015;16:731. https:\/\/doi.org\/10.1208\/s12249-015-0350-9.","journal-title":"AAPS PharmSciTech"},{"key":"648_CR114","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.3390\/ijms21186502","volume":"21","author":"A Teruel","year":"2020","unstructured":"Teruel A, Gonz\u00e1lez-\u00c1lvarez I, Bermejo M, Merino V, Marcos MD, Sancen\u00f3n F, et al. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. International Journal of Molecular Sciences. 2020;21:6502. https:\/\/doi.org\/10.3390\/ijms21186502.","journal-title":"International Journal of Molecular Sciences"},{"key":"648_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105655","volume":"158","author":"A Butreddy","year":"2020","unstructured":"Butreddy A, Bandari S, Repka MA. Quality-by-design in hot melt extrusion based amorphous solid dispersions: an industrial perspective on product development. Eur J Pharm Sci. 2020;158:105655. https:\/\/doi.org\/10.1016\/j.ejps.2020.105655.","journal-title":"Eur J Pharm Sci"},{"key":"648_CR116","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejps.2015.12.008","volume":"87","author":"M Kuentz","year":"2015","unstructured":"Kuentz M, Holm R, Elder D. Methodology of oral formulation selection in the pharmaceutical industry. European Journal of Pharmaceutical Sciences. 2015;87:136. https:\/\/doi.org\/10.1016\/j.ejps.2015.12.008.","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"648_CR117","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpb.2019.05.021","volume":"141","author":"RC Evans","year":"2019","unstructured":"Evans RC, Bochmann ES, Kyeremateng SO, Gryczke A, Wagner K. Holistic QbD approach for hot-melt extrusion process design space evaluation: Linking materials science, experimentation and process modeling. European Journal of Pharmaceutics and Biopharmaceutics. 2019;141:149. https:\/\/doi.org\/10.1016\/j.ejpb.2019.05.021.","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"648_CR118","doi-asserted-by":"publisher","unstructured":"Sahu S, Choudhury PK, Pasa G, Murthy PN, Sahu P, Verma R. Modulation of mesalamine release from enteric-coated matrix tablets using natural polysaccharides for localized colonic delivery. Journal of Applied Pharmaceutical Research 2024;12:93. https:\/\/doi.org\/10.18231\/j.joapr.2024.12.2.93.108 .","DOI":"10.18231\/j.joapr.2024.12.2.93.108"},{"key":"648_CR119","doi-asserted-by":"publisher","unstructured":"Pradyumna D, Srinivas L, Krishna NM. Formulation and evaluation of Mesalamine mini-tablets in enteric-coated capsule for the treatment of Ulcerative colitis using a factorial design approach. Research Journal of Pharmacy and Technology 2024:4035. https:\/\/doi.org\/10.52711\/0974-360x.2024.00626 .","DOI":"10.52711\/0974-360x.2024.00626"},{"key":"648_CR120","doi-asserted-by":"publisher","unstructured":"Suryawanshi D, Shinde U, Jha DK, Amin PD. Application of Quality by Design Approach for Hot-Melt Extrusion Process Optimization. Elsevier eBooks, Elsevier BV; 2019, p. 209. https:\/\/doi.org\/10.1016\/b978-0-12-815799-2.00012-5.","DOI":"10.1016\/b978-0-12-815799-2.00012-5."},{"key":"648_CR121","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jddst.2018.01.008","volume":"44","author":"C Parmar","year":"2018","unstructured":"Parmar C, Parikh K, Mundada PK, Bhavsar D, Sawant K. Formulation and optimization of enteric coated bilayer tablets of mesalamine by RSM: In vitro - In vivo investigations and roentogenographic study. Journal of Drug Delivery Science and Technology. 2018;44:388. https:\/\/doi.org\/10.1016\/j.jddst.2018.01.008.","journal-title":"Journal of Drug Delivery Science and Technology"},{"key":"648_CR122","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2174\/0929867329666220707102912","volume":"30","author":"AG Tavares","year":"2022","unstructured":"Tavares AG, de Ara\u00fajo JTC, Duarte JL, Silvestre ALP, Filippo LDD, Chorilli M. Polymeric Systems for Colon-specific Mesalazine Delivery in theIntestinal Bowel Diseases Management. Current Medicinal Chemistry. 2022;30:1351. https:\/\/doi.org\/10.2174\/0929867329666220707102912.","journal-title":"Current Medicinal Chemistry"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00648-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:07:09Z","timestamp":1789052829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00648-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":122,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00648-4","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}